Levetiracetam ( DrugBank: Levetiracetam )


5 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1
4原発性側索硬化症1
6パーキンソン病6
13多発性硬化症/視神経脊髄炎5
307カナバン病1

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 623 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00324454
(ClinicalTrials.gov)
May 20069/5/2006Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseA Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseMotor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular AtrophyBiological: LevetiracetamDuke UniversityUCB PharmaCompleted18 YearsN/ABoth20Phase 2United States

4. 原発性側索硬化症


臨床試験数 : 7 薬物数 : 17 - (DrugBank : 9) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 32
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00324454
(ClinicalTrials.gov)
May 20069/5/2006Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseA Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseMotor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular AtrophyBiological: LevetiracetamDuke UniversityUCB PharmaCompleted18 YearsN/ABoth20Phase 2United States

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04643327
(ClinicalTrials.gov)
February 9, 202118/11/2020Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's DiseaseDouble-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept StudyParkinson Disease;Mild Cognitive Impairment;Memory ImpairmentDrug: Levetiracetam;Drug: PlaceboThe University of QueenslandQueensland University of Technology;Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women's HospitalRecruitingN/AN/AAll28Phase 2Australia
2NCT00584025
(ClinicalTrials.gov)
December 200721/12/2007Keppra IV for the Treatment of Motor Fluctuations in Parkinson's DiseaseParkinson's DiseaseDrug: levetiracetam;Drug: PlaceboUniversity of South FloridaNULLWithdrawn30 Years80 YearsAll0Phase 4United States
3NCT00291733
(ClinicalTrials.gov)
May 200614/2/2006Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's DiseaseLevetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover TrialLevodopa Induced DyskinesiaDrug: Levetiracetam;Drug: Placebo1st Hospital of Social Security ServicesUCB PharmaActive, not recruiting30 Years80 YearsBoth50Phase 2Greece
4NCT00307450
(ClinicalTrials.gov)
March 200627/3/2006Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's DiseaseEfficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV StudyParkinson's DiseaseDrug: LevetiracetamTechnische Universität DresdenUCB GmbH, Huettenstrasse 205, 50170 Kerpen, GermanyCompleted30 Years80 YearsBoth34Phase 4Germany
5NCT00076674
(ClinicalTrials.gov)
January 200428/1/2004Levetiracetam Treatment of L-dopa Induced DyskinesiasLevetiracetam Treatment of L-dopa Induced DyskinesiasDyskinesias;Parkinson DiseaseDrug: Intravenous LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth40Phase 2United States
6NCT00160576
(ClinicalTrials.gov)
July 20038/9/2005Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome DyskinesiasA Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's DiseaseIdiopathic Parkinson DiseaseDrug: LevetiracetamUCB PharmaNULLCompleted30 YearsN/ABoth30Phase 2NULL

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,380 - (DrugBank : 407) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-005414-40-IT
(EUCTR)
21/12/200728/11/2007Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - NDEfficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - ND Patients with an established and stable Multiple Sclerosis (according to Poser criteria).
MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis
Trade Name: KEPPRA
INN or Proposed INN: Levetiracetam
AZIENDA SANITARIA N. 3 GENOVESENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
2NCT00423527
(ClinicalTrials.gov)
January 200716/1/2007Levetiracetam in Central Pain in Multiple Sclerosis(MS)Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple SclerosisMultiple SclerosisDrug: levetiracetamOdense University HospitalNULLCompleted18 YearsN/ABoth30Phase 4Denmark
3EUCTR2006-000397-71-DK
(EUCTR)
16/05/200602/05/2006Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosisDouble-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis Trade Name: Keppra
Product Name: Levetiracetam
Product Code: ucb L059
Søren H. Sindrup, Department of Neurology, Odense University HospitalNULLNot RecruitingFemale: yes
Male: yes
30Denmark
4EUCTR2005-003903-35-GB
(EUCTR)
19/01/200619/12/2005 : The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis : The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis Multiple SclerosisTrade Name: Keppra 250mg
INN or Proposed INN: Levetiracetam
Trade Name: Keppra 500mg
Product Name: Keppra ®
Newcastle-upon-Tyne Hospitals NHS TrustNULLNot Recruiting Female: yes
Male: yes
20 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom
5EUCTR2005-001776-13-DE
(EUCTR)
05/08/200526/09/2006Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over studyEfficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study Multiple SclerosisProduct Name: LevetiracetamOrganisation name was not enteredNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
24Germany

307. カナバン病


臨床試験数 : 5 薬物数 : 9 - (DrugBank : 3) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04833907
(ClinicalTrials.gov)
April 1, 202124/3/2021rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan DiseasePhase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of AVASPA Gene Therapy for Treatment of Children With Typical Canavan DiseaseCanavan DiseaseDrug: rAAV-Olig001-ASPA;Drug: Levetiracetam;Drug: PrednisoloneMyrtelle Inc.NULLRecruiting3 Months60 MonthsAll24Phase 1/Phase 2United States